JAK3 Inhibitors In the Fight Against Autoimmune Disease
Autoimmune disorders such as multiple sclerosis, psoriasis, and rheumatoid arthritis (RA), just to name a few, affect millions of people and have various contributing factors that lead to disease; some known and some unknown.   These disorders occur due to the immune system’s failure to discriminate between self vs. foreign entities. Janus Kinase 3 (JAK3) is
Targeting Adenosine Kinase In the Fight Against Neurological Disorders
Could targeting Adenosine Kinase help lead to treatments for neurological disorders and chronic pain? Adenosine, one of four nucleoside building blocks to DNA and RNA, has a shielding effect on a wide range of conditions, including inflammation, various forms of neuronal hyperexcitability, and/or toxicity, including hypoxia, seizures, and chronic pain. This cellular activity modulator brings
NSP13 Inhibitors as COVID-19 Treatments
Could NSP13 be the target to help treat some respiratory infections such as SARS-CoV-2? Respiratory diseases caused by coronaviruses (CoVs) vary in symptoms, severity, and risk. Typically, symptoms are mild and known as the common cold, while others are more severe and lead to pneumonia or bronchitis, chest pains, and possibly death. SARS-CoV and MERS-CoV
PKR Inhibitor Blog
Can a novel PKR inhibitor help lead to new treatments for viral infections? –  While the human immune response is astounding and works hard to keep us alive in the face of the many germs we encounter daily, it is exceedingly complex. Unlike the adaptive immune response, the innate response acts quickly. It is considered
TREX1 Inhibitor Assays
TREX1 Inhibitor assays could help move things forward for cancer and HIV treatments. – The immune system of humans is remarkable. Unlike the adaptive immune response, the innate immune response is quick and is considered the first line of defense against pathogens and foreign DNA. This foreign material can come from pathogens, tumor cells, or
DDX3 inhibitors antiviral therapeutics
DDX3 inhibitors could unlock new treatments for viral diseases. The human immune response is extraordinary and incredibly complex. As the first line of defense against pathogens and foreign DNA, the innate response acts quickly. Viruses activate innate immunity as the host has proteins that recognize viral components. The innate immune response relies on several cell
cGAS Phase II Press Release Graphic
The National Institute of Allergy and Infectious Diseases (NIAID) recently awarded BellBrook Labs a $1.8 million Phase II Small Business Innovative Research (SBIR) grant to develop small molecule antagonists of cyclic GAMP synthase (cGAS). The grant will enable BellBrook to optimize their cGAS lead molecules and test their efficacy for treating lupus-related UV light sensitivity
Performing a Kinase Assay Kit in a Lab
Kinases are essential players in cellular functions such as cell signaling, cellular transport, and protein regulation. For these reasons, many kinases are innate immunity targets. A kinase assay kit is ideal whether used for drug screening and dose-response measurements or detection when studying a particular cellular pathway. A universal ADP assay allows researchers to screen
Small GTPase Modulation
Cancer is complex, which makes determining the culprit as well as individual treatment extremely challenging. A variety of cancer types exist with a multitude of contributors. As the second leading cause of death in the US, cancer has been a target scientists have been battling for decades. When DNA is damaged or mutations occur, cells
TREX1 Press Release Graphic
The National Cancer Institute (NCI) recently awarded BellBrook Labs a $300,000 Phase I Small Business Innovative Research (SBIR) grant to develop tools for discovering small-molecule antagonists of TREX1, a checkpoint at the top of the critical immunostimulatory STING pathway. Madison, WI – March 2021 – BellBrook Labs has been awarded a $300,000 Phase I Small